Glaukos GKOS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Glaukos (GKOS) Business Model and Operations Summary
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Key Insights
Glaukos (GKOS) Core Market Data and Business Metrics
Latest Closing Price
$97.09Market Cap
$5.53 BillionPrice-Earnings Ratio
-35.05Total Outstanding Shares
56.57 Million SharesTotal Employees
995Dividend
No dividendIPO Date
June 25, 2015SIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
New York Stock ExchangeHeadquarters
1 Glaukos Way, Aliso Viejo, CA, 92656
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $91.54 Million |
| Net Cash Flow From Operating Activities | $-61.32 Million |
| Net Cash Flow, Continuing | $78.05 Million |
| Net Cash Flow From Investing Activities, Continuing | $47.83 Million |
| Net Cash Flow From Investing Activities | $47.83 Million |
| Net Cash Flow From Operating Activities, Continuing | $-61.32 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Operating Income/Loss | $-122.37 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Basic Earnings Per Share | $-2.77 |
| Operating Expenses | $411.82 Million |
| Diluted Average Shares | $52.76 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-144.92 Million |
| Comprehensive Income/Loss | $-144.92 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $1.45 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $62.10 Million |
| Fixed Assets | $97.87 Million |
| Liabilities And Equity | $974.76 Million |
| Other Current Assets | $392.11 Million |
| Current Liabilities | $75.13 Million |
| Equity | $766.93 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||